Literature DB >> 3472642

WiDr is a derivative of another colon adenocarcinoma cell line, HT-29.

T R Chen, D Drabkowski, R J Hay, M Macy, W Peterson.   

Abstract

This paper documents chromosomal and isozymic evidence indicating that WiDr is a derivative of another colon adenocarcinoma cell line, HT-29, which was established in 1964. The phenotypes for seven isozymes studied were identical for all HT-29 and WiDr cell lines. The karyotypes were similar between four HT-29 cultures separated by more than 100 passages and two WiDr cultures that were studied independently in 1979 and 1985. The isozymic and karyotypic data are consistent with that described for the cell line WiDr, originally reported in 1979. Detailed karyotypic comparisons further show that cultures of WiDr possess all nine chromosomal markers found in the initial HT-29 (passage 19) cultures. However, both the higher passaged HT-29 and WiDr differ from the initial HT-29 (passage 19) because it has an additional five to eight constitutive marker chromosomes. An increase or decrease of one copy in several normal chromosomes is also noticed with more normal chromosome gains than losses. The study provides another example demonstrating the remarkable karyotypic stability within a heteroploid cell line with continued passage. It also reemphasizes the critical need for detailed karyotypic and isoenzymic studies on all cell lines in common use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472642     DOI: 10.1016/0165-4608(87)90267-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  22 in total

Review 1.  Colorectal cancer models for novel drug discovery.

Authors:  Daniel Golovko; Dmitriy Kedrin; Ömer H Yilmaz; Jatin Roper
Journal:  Expert Opin Drug Discov       Date:  2015-08-21       Impact factor: 6.098

2.  Bumetanide Derivatives AqB007 and AqB011 Selectively Block the Aquaporin-1 Ion Channel Conductance and Slow Cancer Cell Migration.

Authors:  Mohamad Kourghi; Jinxin V Pei; Michael L De Ieso; Gary Flynn; Andrea J Yool
Journal:  Mol Pharmacol       Date:  2015-10-14       Impact factor: 4.436

3.  A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

Authors:  Anna Ressa; Evert Bosdriesz; Joep de Ligt; Sara Mainardi; Gianluca Maddalo; Anirudh Prahallad; Myrthe Jager; Lisanne de la Fonteijne; Martin Fitzpatrick; Stijn Groten; A F Maarten Altelaar; René Bernards; Edwin Cuppen; Lodewyk Wessels; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2018-07-03       Impact factor: 5.911

4.  Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability.

Authors:  Anna V Roschke; Kristen Stover; Giovanni Tonon; Alejandro A Schäffer; Ilan R Kirsch
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

5.  Comparative study of the expression of Rb and p53 genes in human colorectal cancers, colon carcinoma cell lines and synchronized human fibroblasts.

Authors:  M L Gope; M Chun; R Gope
Journal:  Mol Cell Biochem       Date:  1991-09-18       Impact factor: 3.396

6.  Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability.

Authors:  Masakazu Yashiro; Kosei Hirakawa; C Richard Boland
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

7.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

8.  Single molecule force measurements of perlecan/HSPG2: A key component of the osteocyte pericellular matrix.

Authors:  Sithara S Wijeratne; Jerahme R Martinez; Brian J Grindel; Eric W Frey; Jingqiang Li; Liyun Wang; Mary C Farach-Carson; Ching-Hwa Kiang
Journal:  Matrix Biol       Date:  2015-11-04       Impact factor: 11.583

9.  Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression.

Authors:  Yong-Sam Kim; Yeong Hee Ahn; Kyoung Jin Song; Jeong Gu Kang; Ju Hee Lee; Seong Kook Jeon; Hyoung-Chin Kim; Jong Shin Yoo; Jeong-Heon Ko
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

10.  Analysis of interactions of Salmonella type three secretion mutants with 3-D intestinal epithelial cells.

Authors:  Andrea L Radtke; James W Wilson; Shameema Sarker; Cheryl A Nickerson
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.